Patents by Inventor Hiroko Iwanari

Hiroko Iwanari has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CADM1 V9-recognizing antibody
    Patent number: 11891443
    Abstract: The present invention provides an antibody recognizing a v9 fragment of the cell adhesion molecule CADM1.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: February 6, 2024
    Assignee: The University of Tokyo
    Inventors: Yoshinori Murakami, Takeshi Ito, Takao Hamakubo, Hiroko Iwanari
  • CADM1 V9-Recognizing Antibody
    Publication number: 20210079092
    Abstract: The present invention provides an antibody recognizing a v9 fragment of the cell adhesion molecule CADM1.
    Type: Application
    Filed: March 18, 2019
    Publication date: March 18, 2021
    Inventors: Yoshinori Murakami, Takeshi Ito, Takao Hamakubo, Hiroko Iwanari
  • METHOD FOR KILLING TUMOR CELLS AND COMPOSITION USED THEREFOR
    Publication number: 20200147233
    Abstract: It is an object of the present invention to provide a method for killing tumor cells, having a few side effects. The present invention provides a method for killing tumor cells, comprising: (1) a step of allowing an immunotoxin formed by binding an antibody binding to ROBO1 or a fragment thereof to a cytotoxin to come into contact with tumor cells; (2) a step of allowing a photosensitizer that induces photochemical cytoplasmic internalization to come into contact with the tumor cells; and (3) a step of irradiating the tumor cells with a wave length that is effective for activating the sensitizer, so as to kill the cells.
    Type: Application
    Filed: October 3, 2019
    Publication date: May 14, 2020
    Applicant: PhotoQ3 Inc.
    Inventors: Takao HAMAKUBO, Noriko KOMATSU, Kenichi MITSUI, Osamu ARAI, Hiroko IWANARI, Tsuyoshi TAKATO, Takahiro ABE
  • Monoclonal antibody specifically recognizing asparagine synthetase
    Patent number: 9638697
    Abstract: It is an object of the present invention to provide a monoclonal antibody, which is suitable for the quantitative analysis of asparagine synthetase in a cell. The present invention provides a monoclonal antibody which specifically recognizes asparagine synthetase that is present in a cell.
    Type: Grant
    Filed: October 3, 2012
    Date of Patent: May 2, 2017
    Assignees: THE UNIVERSITY OF TOKYO, INSTITUTE OF IMMUNOLOGY CO., LTD., AICHI MEDICAL UNIVERSITY
    Inventors: Takao Hamakubo, Yasuhiro Mochizuki, Hiroko Iwanari, Osamu Arai, Toshiyuki Kitoh, Masahito Tsurusawa
  • Monoclonal antibody, and use thereof
    Patent number: 9155805
    Abstract: [Theme] To provide a monoclonal antibody against human GPR87. Also, to provide a novel means for diagnosing or treating a malignant tumor. [Solution means] Monoclonal antibodies against human GPR87 are provided. The antibodies can recognize human GPR87, which is expressed on a cell membrane while retaining a three-dimensional structure, and can recognize GPR87, which is expressed in a cell endogenously with an epitope being present in an extracellular domain of full-length human GPR87. The antibodies are thus useful in biochemical analysis, etc., of GPR87, useful in immunohistological diagnosis, etc., of squamous cell carcinoma, and also potentially useful in PET diagnosis, antibodies for treatment, etc., of squamous cell carcinoma.
    Type: Grant
    Filed: February 20, 2010
    Date of Patent: October 13, 2015
    Assignees: PERSEUS PROTEOMICS INC., THE UNIVERSITY OF TOKYO
    Inventors: Takao Hamakubo, Yasuhiro Mochizuki, Hiroyuki Aburatani, Hiroko Iwanari, Shunsuke Niwa, Yoshiko Nakada
  • MONOCLONAL ANTIBODY SPECIFICALLY RECOGNIZING ASPARAGINE SYNTHETASE
    Publication number: 20140322726
    Abstract: It is an object of the present invention to provide a monoclonal antibody, which is suitable for the quantitative analysis of asparagine synthetase in a cell. The present invention provides a monoclonal antibody which specifically recognizes asparagine synthetase that is present in a cell.
    Type: Application
    Filed: October 3, 2012
    Publication date: October 30, 2014
    Inventors: Takao Hamakubo, Yasuhiro Mochizuki, Hiroko Iwanari, Osamu Arai, Toshiyuki Kitoh, Masahito Tsurusawa
  • Therapeutic agents for alzheimer's disease and cancer
    Patent number: 8398981
    Abstract: To provide a therapeutic drug for Alzheimer's disease and/or a cancer. The therapeutic drug for Alzheimer's disease and/or a cancer contains an anti-nicastrin antibody, a derivative of the antibody, or a fragment of the antibody or the derivative.
    Type: Grant
    Filed: October 19, 2011
    Date of Patent: March 19, 2013
    Assignees: The University of Tokyo, Perseus Proteomics Inc.
    Inventors: Takeshi Iwatsubo, Tatsuhiko Kodama, Takao Hamakubo, Taisuke Tomita, Ikuo Hayashi, Yasuomi Urano, Hiroko Iwanari, Masao Ohkuchi
  • Therapeutic agents for alzheimer's disease and cancer
    Patent number: 8394376
    Abstract: To provide a therapeutic drug for Alzheimer's disease and/or a cancer. The therapeutic drug for Alzheimer's disease and/or a cancer contains an anti-nicastrin antibody, a derivative of the antibody, or a fragment of the antibody or the derivative.
    Type: Grant
    Filed: December 7, 2010
    Date of Patent: March 12, 2013
    Assignees: The University of Tokyo, Perseus Proteomics Inc.
    Inventors: Takeshi Iwatsubo, Tatsuhiko Kodama, Takao Hamakubo, Taisuke Tomita, Ikuo Hayashi, Yasuomi Urano, Hiroko Iwanari, Masao Ohkuchi
  • Diagnostic agent and therapeutic agent for pancreatic cancer
    Patent number: 8273859
    Abstract: The present invention provides a novel diagnostic or therapeutic method for pancreatic cancer employing a blood marker. The present invention provides a diagnostic or therapeutic drug for pancreatic cancer containing an anti-AMIGO2 antibody.
    Type: Grant
    Filed: July 14, 2011
    Date of Patent: September 25, 2012
    Assignees: Perseus Proteomics Inc., The University of Tokyo
    Inventors: Hiroyuki Aburatani, Hiroko Iwanari, Isao Kohno
  • Diagnostic agent and therapeutic agent for pancreatic cancer
    Patent number: 8211630
    Abstract: The present invention provides a novel diagnostic or therapeutic method for pancreatic cancer employing a blood marker. The present invention provides a diagnostic or therapeutic drug for pancreatic cancer containing an anti-AMIGO2 antibody.
    Type: Grant
    Filed: April 18, 2007
    Date of Patent: July 3, 2012
    Assignees: Perseus Proteomics Inc., The University of Tokyo
    Inventors: Hiroyuki Aburatani, Hiroko Iwanari, Isao Kohno
  • THERAPEUTIC AGENTS FOR ALZHEIMER'S DISEASE AND CANCER
    Publication number: 20120128694
    Abstract: To provide a therapeutic drug for Alzheimer's disease and/or a cancer. The therapeutic drug for Alzheimer's disease and/or a cancer contains an anti-nicastrin antibody, a derivative of the antibody, or a fragment of the antibody or the derivative.
    Type: Application
    Filed: October 19, 2011
    Publication date: May 24, 2012
    Applicants: PERSEUS PROTEOMICS INC., THE UNIVERSITY OF TOKYO
    Inventors: TAKESHI IWATSUBO, TATSUHIKO KODAMA, TAKAO HAMAKUBO, TAISUKE TOMITA, IKUO HAYASHI, YASUOMI URANO, HIROKO IWANARI, MASAO OHKUCHI
  • NOVEL MONOCLONAL ANTIBODY, AND USE THEREOF
    Publication number: 20120003149
    Abstract: [Theme] To provide a monoclonal antibody against human GPR87. Also, to provide a novel means for diagnosing or treating a malignant tumor. [Solution means] Monoclonal antibodies against human GPR87 are provided. The antibodies can recognize human GPR87, which is expressed on a cell membrane while retaining a three-dimensional structure, and can recognize GPR87, which is expressed in a cell endogenously with an epitope being present in an extracellular domain of full-length human GPR87. The antibodies are thus useful in biochemical analysis, etc., of GPR87, useful in immunohistological diagnosis, etc., of squamous cell carcinoma, and also potentially useful in PET diagnosis, antibodies for treatment, etc., of squamous cell carcinoma.
    Type: Application
    Filed: February 20, 2010
    Publication date: January 5, 2012
    Inventors: Takao Hamakubo, Yasuhiro Mochizuki, Hiroyuki Aburatani, Hiroko Iwanari, Shunsuke Niwa, Yoshiko Nakada
  • DIAGNOSTIC AGENT AND THERAPEUTIC AGENT FOR PANCREATIC CANCER
    Publication number: 20110288278
    Abstract: The present invention provides a novel diagnostic or therapeutic method for pancreatic cancer employing a blood marker. The present invention provides a diagnostic or therapeutic drug for pancreatic cancer containing an anti-AMIGO2 antibody.
    Type: Application
    Filed: July 14, 2011
    Publication date: November 24, 2011
    Applicants: The University of Tokyo, Perseus Proteomics Inc.
    Inventors: Hiroyuki Aburatani, Hiroko Iwanari, Isao Kohno
  • THERAPEUTIC AGENTS FOR ALZHEIMER'S DISEASE AND CANCER
    Publication number: 20110165179
    Abstract: To provide a therapeutic drug for Alzheimer's disease and/or a cancer. The therapeutic drug for Alzheimer's disease and/or a cancer contains an anti-nicastrin antibody, a derivative of the antibody, or a fragment of the antibody or the derivative.
    Type: Application
    Filed: December 7, 2010
    Publication date: July 7, 2011
    Applicants: The University of Tokyo, Perseus Proteomics Inc.
    Inventors: Takeshi IWATSUBO, Tatsuhiko Kodama, Takao Hamakubo, Taisuke Tomita, Ikuo Hayashi, Yasuomi Urano, Hiroko Iwanari, Masao Ohkuchi
  • Method of measuring PTX3 with high sensitivity
    Patent number: 7955807
    Abstract: To provide a method of determining vasculopathy, which is a risk factor of myocardial infarction, angiopathic dementia, etc., at an early stage thereof (i.e., mild vasculopathy). The present invention provides a method of determining the severity of mild vasculopathy, including determining PTX3 level in an assay sample by use of an anti-PTX3 monoclonal antibody.
    Type: Grant
    Filed: November 10, 2006
    Date of Patent: June 7, 2011
    Assignees: The University of Tokyo, Perseus Proteomics Inc.
    Inventors: Tatsuhiko Kodama, Takao Hamakubo, Koji Maemura, Akira Sugiyama, Hiroko Iwanari, Isao Kohno, Yukio Ito
  • Tumor diagnostic agent used in PET comprising anti-ROBO1 antibody
    Patent number: 7875705
    Abstract: It is an object of the present invention to provide a novel antibody capable of specifically recognizing ROBO1 that is expressed in a cell membrane, a hybridoma that produces the above antibody, a method for producing the above antibody, and a tumor diagnostic agent used in PET comprising the above antibody. The present invention provides a monoclonal antibody capable of specifically recognizing ROBO1 existing on the surface of a cell, which is obtained by immunizing an animal to be immunized with a ROBO1-displaying budded baculovirus recovered from the culture supernatant of host cells infected with a recombinant baculovirus comprising the full-length cDNA of ROBO1 as an antigen.
    Type: Grant
    Filed: November 28, 2007
    Date of Patent: January 25, 2011
    Assignees: The University of Tokyo, Perseus Proteomics Inc.
    Inventors: Hiroko Iwanari, Isao Kohno, Takao Hamakubo, Yoshitaka Kumakura, Hirotaka Itoh, Toshiko Sakihama, Hiroyuki Aburatani, Toshimitsu Momose
  • DIAGNOSTIC AGENT AND THERAPEUTIC AGENT FOR PANCREATIC CANCER
    Publication number: 20100316568
    Abstract: The present invention provides a novel diagnostic or therapeutic method for pancreatic cancer employing a blood marker. The present invention provides a diagnostic or therapeutic drug for pancreatic cancer containing an anti-AMIGO2 antibody.
    Type: Application
    Filed: April 18, 2007
    Publication date: December 16, 2010
    Applicants: Perseus Proteomics Inc., The University of Tokyo
    Inventors: Hiroyuki Aburatani, Hiroko Iwanari, Isao Kohno
  • Method for predicting and judging the recurrence of liver cancer after treating liver cancer
    Patent number: 7691586
    Abstract: A method for prognosing possible recurrence after treatment of the liver cancer, characterized by measuring GPC3 contained in a test sample by use of an anti-GPC3 antibody.
    Type: Grant
    Filed: April 28, 2005
    Date of Patent: April 6, 2010
    Assignee: Perseus Proteomics Inc.
    Inventors: Kiyotaka Watanabe, Shin Ohnishi, Hiroyuki Aburatani, Yutaka Midorikawa, Yoshitaka Hippo, Hiroko Iwanari, Susumu Tokita, Hirokazu Satoh
  • Method Of Measuring PTX3 With High Sensitivity
    Publication number: 20100062449
    Abstract: To provide a method of determining vasculopathy, which is a risk factor of myocardial infarction, angiopathic dementia, etc., at an early stage thereof (i.e., mild vasculopathy). The present invention provides a method of determining the severity of mild vasculopathy, including determining PTX3 level in an assay sample by use of an anti-PTX3 monoclonal antibody.
    Type: Application
    Filed: November 10, 2006
    Publication date: March 11, 2010
    Applicants: The University of Tokyo, Perseus Proteomics Inc.
    Inventors: Tatsuhiko Kodama, Takao Hamakubo, Koji Maemura, Akira Sugiyama, Hiroko Iwanari, Isao Kohno, Yukio Ito
  • DRUG FOR DIAGNOSING LARGE INTESTINAL CANCER AND/OR POLYP, OBSERVING POSTOPERATIVE COURSE AND MONITORING RECURRENCE
    Publication number: 20100041167
    Abstract: The present invention is directed to a method for diagnosing large intestinal cancer and/or polyp and a method for observing postoperative course or monitoring recurrence thereof, wherein each method includes detecting cystatin SN protein by use of an anti-cystatin SN antibody. The present invention is able to provide a kit for assaying cystatin SN, which can be used, in a simple manner, in a diagnosis performed prior to conventional barium enema examination and endoscopic examination which impose burdens on patients; as an indicator of metastasis and recurrence; and in the evaluation of therapeutic effects. The present invention provides a method for diagnosing or monitoring large intestinal cancer and/or polyp which can be performed in a simple manner, and thus can allow to design a new regimen rapidly.
    Type: Application
    Filed: December 14, 2005
    Publication date: February 18, 2010
    Applicants: Perseus Proteomics Inc., The University of Tokyo
    Inventors: Hiroyuki Aburatani, Takahiro Shimamura, Kiyotaka Watanabe, Takeharu Asano, Shin Ohnishi, Takao Hamakubo, Akira Sugiyama, Naoki Hosomi, Hiroko Iwanari, Keisuke Ishii